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Sentinel lymph node (SLN) status is highly predictive of
overall axillary lymph node involvement in breast can-
cer. Historically, SLN-positive patients have undergone
axillary lymph node dissection in a second surgery.
Intraoperative SLN analysis could reduce the cost and
complications of a second surgery; however, existing
histopathological methods lack standardization and ex-
hibit poor sensitivity. Rapid molecular methods may
lead to improved intraoperative diagnosis of SLNmetas-
tasis. In this study, we used a genome-wide gene expres-
sion analysis of breast and other tissues to identify
seven putative markers for detecting breast cancer me-
tastasis. We assessed the utility of these markers for
identifying clinically actionable metastases in lymph
nodes through reverse transcriptase-polymerase chain
reaction analysis of SLNs from 254 breast cancer pa-
tients. Polymerase chain reaction signals were com-
pared to pathology on a per-patient basis. The optimal
two-gene combination, mammaglobin and cytokeratin
19, detected clinically actionable metastasis in breast
SLNs with 90% sensitivity and 94% specificity. Applica-
tion of stringent criteria for identifying presumptive
hematoxylin- and eosin-positive samples increased sen-
sitivity and specificity to 91 and 97%, respectively. This
study represents the first comprehensive demonstra-
tion of the utility of gene expressionmarkers for detect-
ing clinically actionable breast metastases. An intraop-
erative molecular assay using these markers has the
potential to significantly reduce second surgeries for
patients undergoing SLN dissection. (J Mol Diagn
2005, 7:327–336)
Breast cancer is second only to lung cancer in mortality
among women worldwide.1 In the care of this significant
disease, the evaluation of blood, bone marrow, and
lymph nodes for the presence of metastatic cells is an
important component of disease characterization and
management.2–6 The method for assessment of these
peripheral tissues is largely dependent on histological
and cytological methods. Detection of metastasis in
lymph nodes is typically accomplished by hematoxylin
and eosin (H&E) and antibody staining of lymph node
sections.7,8 Analysis of bone marrow samples, although
still in development, currently involves antibody staining
of cytological smears. For some time, there has been
discussion about the potential for the use of molecular
biological tools to supplement or to improve existing
methods.9 Molecular methods such as reverse transcrip-
tase-polymerase chain reaction (RT-PCR) offer increased
analytical sensitivity compared with standard histological
methods.10–12 In addition, nucleic acid-based detection
methods such as real-time PCR offer the potential of
rapid and sensitive point-of-care testing and the applica-
tion of objective quantitative assay cut-offs.
A clear intersection between these features is the in-
traoperative assessment of sentinel lymph nodes (SLNs)
for the presence of clinically actionable metastasis, a
level of metastasis that would be expected to consistently
lead to a subsequent axillary lymph node (ALN) dissec-
tion. In the SLN dissection procedure,13–15 radioactive
and colored tracers are injected around the tumor to
identify the SLN(s). A lack of metastasis in SLN is highly
predictive of a lack of overall ALN metastasis.16,17 If SLN
metastasis is detected by histological analysis, the re-
maining ALNs are typically removed in a secondary sur-
gical procedure as a therapeutic measure and to facili-
tate patient staging. Because of the high frequency of
postsurgical morbidity18,19 associated with axillary lymph
node dissection (ANLD), the SLN dissection procedure
has emerged as the standard of care. To streamline the
SLN process, many institutions have adopted intraoper-
ative SLN analysis methods such as imprint cytology and
frozen section analysis; however, these histological meth-
ods suffer from poor and variable sensitivity and a lack of
standardization.20–22 The development of a rapid RT-
PCR assay based on gene expression markers of metas-
tasis would represent a major step forward for the field of
intraoperative SLN analysis and for the application of
molecular diagnostic technology at the point of surgery.
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To fulfill this need, a gene marker is required that
satisfies the analytical requirements for this assay. An
ideal marker would have close to 100% specificity and
sensitivity substantially greater than current intraopera-
tive methods. Based on existing literature, it is likely that
multiple markers may be required to achieve optimal
correlation with histology. Here, we describe a study
commencing with a genome-wide survey for breast tis-
sue-specific and breast cancer status markers, conclud-
ing with in-depth characterization of candidate markers in
sentinel lymph nodes, to identify the ideal markers for the
detection of clinically actionable metastases in SLNs.
Materials and Methods
Selection of Markers from an Expressed
Sequence Tag (EST) Database
Putative breast-specific and breast cancer status mark-
ers were identified using the Incyte EST database. Initial
screening of markers was based on analysis of 325,539
ESTs from 35 normal breast tissue libraries, 179,640
ESTs from 25 breast tumor libraries, and 332,558 ESTs
from 40 peripheral blood libraries. For each gene ana-
lyzed, the frequency of its ESTs in normal breast tissue,
breast tumor, and peripheral blood was determined. If
more than one EST was observed in the peripheral blood
libraries, the marker was eliminated from further consid-
eration. For each EST from genes that passed this initial
screen, a Fisher’s exact test was used 1) to compare its
frequencies in normal breast and peripheral blood; 2) to
compare its frequencies in breast tumor and peripheral
blood; and 3) to compare its frequencies in normal breast
and breast tumor. If the P values of both comparisons 1
and 2 were less than 0.01 and the level of expression in
breast tissue and breast tumor was higher than in periph-
eral blood, the gene was selected for analysis as a po-
tential breast tissue-specific marker. If the P values of all
comparisons (1, 2, and 3) were less than 0.01 and the
expression level in breast tumor was higher than in breast
tissue, the EST was selected as a potential breast cancer
status marker. For each of the potential breast tissue-
specific markers, the number of ESTs observed in colon,
lung, and ovarian libraries was determined. If more than
one EST was found in any one of the tissues, the marker
was eliminated. Selected markers were used to search
literature databases. Markers previously implicated in
breast cancers were given highest priority, although a
subset of the markers tested were previously
unpublished.
DNA Microarray Samples and Methods
Five hundred and fifty-two primary cancer, 29 benign
proliferative epithelial lesions, and 143 normal snap-
frozen human tissue specimens were obtained from
Genomics Collaborative, Inc. (Cambridge, MA), Clinom-
ics Biosciences, Inc. (Pittsfield, MA), Washington Univer-
sity (St. Louis, MO), and Erasmus Medical Center (Rot-
terdam, The Netherlands). Tissue was collected and
studied under a protocol approved by the respective
Institutional Review Board. Each sample was examined
for its histopathological features, preservation, and tumor
content.
From cancer samples with 70% tumor cells, benign
and normal samples were dissected and homogenized
with mechanical homogenizer (IKA T8 Ultra-Turrax,
Staufen, Germany) in Trizol reagent (Invitrogen, Carls-
bad, CA). Total RNA was isolated from Trizol reagent and
precipitated at20°C with isopropyl alcohol. RNA pellets
were washed with 75% ethanol, resuspended in water,
and stored at 80°C until use. RNA integrity was exam-
ined with Agilent 2100 Bioanalyzer RNA 6000 Nano As-
say (Agilent Technologies, Inc., Palo Alto, CA). This study
used the Human U133a high-density array (Affymetrix,
Santa Clara, CA). RNA amplification, labeling, hybridiza-
tion, and scanning were all performed by the standard
protocols from Affymetrix. The arrays were stained with
streptavidin-phycoerythrin (Molecular Probes, Eugene,
OR) and scanned using the GeneArray scanner from
Affymetrix. Image analysis was performed by using
GeneChip MAS 5.0 software from Affymetrix. Expression
levels of the probe sets were measured in the RNA sam-
ples covering normal, benign, and cancerous tissues
from breast, colon, lung, ovarian, prostate, and periph-
eral blood leukocytes from healthy donors. A quality con-
trol procedure was then performed to eliminate the poor
signal chips. The first criterion was that the percentage of
the genes with a “present” call on a chip needed to be
33%. The second was that the scaling factor of a chip
needed to be smaller than 15 when scaled to an average
target intensity of 600. The distribution of samples that
met these criteria is summarized in Table 1. This set of
samples was used to identify putative genes through a
process of negative selection filters. To exclude genes
expressed in leukocytes from consideration, any probe
set with a detection P value 0.05 in at least one leuko-
cyte sample by the default setting of the Affymetrix MAS
5.0 software was removed from further analysis. In total,
7567 probe sets were selected. Next, any probe set that
did not at least once fall below the 0.05 detection P value
limit in any of the samples other than leukocyte was
excluded. The resulting gene set contained 4660 probe
sets.
To select individual genes specific for the breast sam-
ples, the following procedure was performed: 1) genes
were selected that had “absent” calls in the blood sam-
ples; 2) the 30th, 50th, and 70th percentiles of gene
expression signal in breast cancer samples were deter-
Table 1. Sample Summary for Microarray Analysis
Number of Samples
Tumor Normal Benign Total
Breast 318 14 6 338
Colon 128 39 0 167
Lung 45 38 1 84
Ovary 22 32 0 54
Prostate 39 8 22 69
Blood 0 12 0 12
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mined for each gene, as well as the maximum observed
expression in other tissues; 3) genes were selected as
candidate breast tissue-specific markers if the 30th, 50th,
and 70th percentiles of gene expression signal in breast
cancer samples was higher than the maximum level of
gene expression in other tissues; and 4) genes were
selected as candidate breast cancer status markers if the
70th percentile of breast cancer expression exhibited a
minimum twofold higher expression in the breast cancer
samples versus the maximum expression level observed
in normal breast tissue.
Clinical Tissue Sample for PCR Screening
Analysis
A total of 129 breast tissue and RNA samples were pro-
cured from a variety of commercial sources. For tissue
samples, RNA was prepared by a standard Trizol method-
ology. The breast RNA samples tested included: 19 normal
breast, 12 benign breast disease, 12 ductal carcinoma in
situ, 2 lobular carcinoma in situ, and all common types of
invasive breast cancer (55 ductal, 19 lobular, 5 mucinous, 3
tubular, and 2 medullary). Twenty-four tissue RNA samples
from lung, colon, rectum, and ovary (6 normal and 18 can-
cerous; procured from Biochain, Inc.) were used as tissue
specificity samples, along with a white blood cell (WBC)
total RNA pool derived from 24 female blood donors with no
history of cancer. Reverse transcription was carried out with
the Superscript II First Strand cDNA Synthesis kit (Invitro-
gen), essentially as per manufacturer’s instructions. SYBR
Green-based quantitative PCR (at least two amplicons per
gene) was carried out using universal amplification/detec-
tion conditions developed at Veridex. For all tissue RNAs,
the assumption was made that each cell contains 10 pg of
total RNA. For WBCs, the level of RNA was empirically
determined to be 0.5 pg/cell.
Sentinel Lymph Node Patient Samples
Sentinel lymph node RNA samples were made available
from the East Carolina University/Anne Arundel Medical
Center multicenter trial. This trial is designed to determine
the utility of qualitative PCR detection of molecular markers
in lymph nodes to predict breast cancer relapse in patients
undergoing SLN dissection procedures. All patients under-
went a complete axillary dissection after the SLN dissection.
As part of the trial protocol, all SLN false-negative patients
(H&E-positive patients with no H&E-positive SLNs) were
excluded from the trial. The protocol was approved by the
Institutional Review Board of each participating site. For
these evaluations, alternating serial sections of the SLNs
were allotted for permanent section H&E histological anal-
ysis or quick-frozen for gene expression studies. RNA was
extracted from tissue representing approximately one-half
of each node using a Trizol method as previously de-
scribed.11 The SLN RNA samples were received by Veridex
and tested for expression of RNA markers in a blinded
fashion (in the absence of any patient identifiers or associ-
ated clinical and pathological information).
Pathological Analysis of Sentinel Lymph Nodes
SLN tissue sections allotted for standard pathology were
fixed in formalin, processed, and embedded in paraffin.
Permanent section H&E histological analysis was carried
at four levels on all blocks, with three unstained sections
set aside at each level. Most, but not all, sites carried out
AE1:3 cytokeratin immunohistochemical analysis on all
nodes negative for metastases by H&E, following the
lab’s standard protocols.
Lymph Node RNA Quality Control
RNA quality was assessed by Agilent, spectroscopy, and
housekeeping gene PCR analyses. The RNA 6000 Nano
Assay (Agilent Technologies) was carried out according
to manufacturer’s protocol. Spectroscopic analysis of
RNA was carried out using the Gene Spec III UV-VIS
spectrophotometer (MiraiBio, Inc., Alameda, CA). House-
keeping gene PCR was performed as described in the
PCR section. We empirically determined that housekeep-
ing gene analysis was most predictive of sample ade-
quacy. RNA samples were considered to be of poor
quality if either of the housekeeping genes gave signals
that were at least 3.5 cycles above the mean of lymph
node samples tested. If at least one node from a patient
was deemed to be of poor quality, the patient was re-
moved from the study unless considered PCR positive for
at least one of the breast markers. There were 254 pa-
tients and 503 lymph nodes included in the final data set
from this study.
Reverse Transcription and Quantitative
Polymerase Chain Reaction for Lymph Node
RNA Samples
The RNA was reverse transcribed before PCR. Five mi-
crograms of RNA and 25 ng/l Oligo dT(12–18) (Invitro-
gen) were incubated at 65°C for 7 minutes and then
placed on ice. The following was then included in the
above mix: 1 Superscript first strand buffer, 10 mmol/L
dithiothreitol, 0.5 mmol/L dNTP, 10 U/l M-MLV (Moloney
murine leukemia virus) reverse transcriptase (RT) (Invitro-
gen), 0.25 U/l RNasin (Promega, Madison, WI), and in a
final reaction volume of 20 l. The mix was then incu-
bated at 37°C for 60 minutes and then at 95°C for 5
minutes. The cDNA was then diluted 1:5 in water and
stored at 20°C.
TaqMan assays were developed and/or validated for the
following seven gene expression markers: mammaglobin
(MG),23–25 cytokeratin 19 (CK19),26 prolactin-induced pro-
tein (PIP),10 B305D (C-form and A-form),27,28 -aminobu-
tyric acid A receptor, pi (GABA-pi),27,28 B726,27,28 and
prostate-derived ets transcription factor (PDEF).29,30 Por-
phobilinogen deaminase31 and -actin were used as
housekeeping genes. Primers and hydrolysis probes for
each assay are listed in Table 2. All assays were designed
to be specific for RNA targets, although the CK19 design
was demonstrated to have low-level cross-reactivity with
CK19 pseudogene DNA. -Actin primers and probe se-
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quences were as recommended by Applied Biosystems
(Foster City, CA) (TaqMan -actin control reagents, part
401846). All probes were used at a final concentration of
0.04 mol/L, and all primers were at 0.3 mol/L. Quantita-
tion of gene-specific RNA was carried out on the ABI Prism
79000HT sequence detection systems (Applied Biosys-
tems). A standard curve was carried out with each thermo-
cycler run that consisted of cDNA generated from target
gene in vitro transcript that was serially diluted into carrier
cDNA from pig lymph node. No target controls were also
included in each assay run to ensure a lack of environmen-
tal contamination. All samples and controls were run in
triplicate.
Two microliters of cDNA template was added into each
50-l reaction. Fifty cycles of PCR were performed with
TaqMan PCR Core Reagents (Applied Biosystems) using
0.0375 U/l AmpliTaq Gold; 1 buffer A; 5 mmol/L
MgCl2; 0.2 mmol/L each of dCTP, dATP, and dGTP; 0.4
mmol/L dUTP; 0.01 U/l AmpErase UNG; 8% glycerol
(Sigma, St. Louis, MO); and 0.01% Tween 20. The follow-
ing cycling parameters were followed: 1 cycle at 50°C for
2 minutes; 1 cycle at 95°C for 10 minutes; and 50 cycles
of 95°C for 15 seconds, 60°C for 1 minute (58°C for B726
only), and 68°C for 1 minute.
Data Analysis
Data were reported in threshold cycles (Ct). The Ct is de-
fined as the cycle at which a statistically significant increase
in normalized reporter emission is seen. Each 1 cycle in-
crease in Ct represents a relative two-fold increase in the
expression level. Samples were unblinded at the conclusion
of the PCR testing. H&E and immunohistochemistry results,
recurrence, and additional pathological data were made
available at such time. Ct cut-offs were established for
determination of positive lymph node status using non-
weighted multivariate receiver operating characteristic
(ROC) analysis. The performances of individual gene mark-
ers and marker combinations were determined on a per
patient basis, using H&E-positive histopathological detec-
tion of metastases (in the absence of supporting immuno-
histochemistry) as the gold standard. Results from B305D
A-form and C-form testing were pooled for analysis pur-
poses, because common primers can be developed that
detect both gene family members.
Determination of Confidence Intervals for
Sensitivity and Specificity
For the marker combination that was considered to give
optimal performance (CK19  mammaglobin), bootstrap
analysis was carried out to determine 95% confidence
ranges for the sensitivity and specificity using the marker
Ct cut-offs determined in this analysis. The resulting con-
fidence intervals were based on 5000 bootstrapping
samples.
Results
Identification of Gene Set for Clinical Testing
The goal of this study was to identify gene expression
markers that had the potential to act as breast-specific
Table 2. TaqMan Assay Primer and Probe Sequences
Gene Type Sequence (5 to 3)
MG F CAAACGGATGAAACTCTGAGCAATGTTGA
R TCTGTGAGCCAAAGGTCTTGCAGA
P TGTTTATGCAATTAATATATGACAGCAGTCTTTGTG
CK19 F AGATGAGCAGGTCCGAGGTTA
R CCTGATTCTGCCGCTCACTATCA
P ACCCTTCAGGGTCTTGAGATTGAGCTGCA
PDEF F GCCGCTTCATTAGGTGGCTCAA
R AGCGGCTCAGCTTGTCGTAGTT
P AAGGAGAAGGGCATCTTCAAAATTGAGGACTCAGC
B305D C-form F* TCTGATAAAGGCCGTACAATG
R* TCACGACTTGCTGTTTTTGCTC
P* ATCAAAAAACAAGCATGGCCTCACACCACT
B305D A-form F GTATCTTCTCAAGATCTGGAAAG
R AAGTCTTGTTCTGGATTGCTGT
P AGTCATCATCATGTAATTTGCCAGTTACT
PIP F GCTTGGTGGTTAAAACTTACC
R TGAACAGTTCTGTTGGTGTA
P CTGCCTGCCTATGTGACGACAATCCGG
GABA-pi F* CAATTTTGGTGGAGAACCCG
R* GCTGTCGGAGGTATATGGTG
P* CATTTCAGAGAGTAACATGGACTACACA
B726 F* GCAAGTGCCAATGATCAGAGG
R* ATATAGACTCAGGTATACACACT
P* TCCCATCAGAATCCAAACAAGAGGAAGATG
Porphobilinogen deaminase F CTGCTTCGCTGCATCGCTGAAA
R CAGACTCCTCCAGTCAGGTACA
P CCTGAGGCACCTGGAAGGAGGCTGCAGTGT
F, forward primer; R, reverse primer; P, probe.
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markers and/or as markers of cancerous breast tissue.
Such markers would have utility for the detection of
breast cancer metastasis in several bodily compart-
ments, including lymph nodes, bone marrow, and blood.
Several methods were used to identify markers specifi-
cally expressed in breast tissues and/or substantially
up-regulated in cancerous breast tissue versus normal
and benign breast tissues. Our marker identification strat-
egy included microarray analysis, analysis of EST librar-
ies in the Incyte database, and searches of primary liter-
ature to identify candidate markers for further analysis.
Markers that passed initial inclusion criteria were then
passed through a series of RT-PCR-based filters to iden-
tify optimal breast tissue markers and breast cancer sta-
tus markers. A subset of these genes then underwent
further large-scale validation to demonstrate clinical utility
for the detection of clinically actionable metastasis in
breast SLNs (for process flow chart, see Figure 1). Table
2 provides the names of the putative markers selected for
RT-PCR analysis and also summarizes the results of the
testing that was done with these markers.
All selected markers were initially screened by RT-PCR
for absolute expression level in a WBC RNA pool. Mark-
ers with significant expression (0.1 copy/cell) in the
WBC pool were eliminated from further screening. Mark-
ers that passed this criterion were then screened with 69
Table 3. Markers Tested and Testing Summary
Breast
marker
type
Identification
method Mode of marker failure
Marker
adequate?Tissue Cancer Incyte
Micro-
array
Lite-
rature
Low
breast
expression
High
WBC
expression
Tissue
cross-
reactivity
Inadequate up-
regulation
Putative breast-specific markers
Mammaglobin X X X X NA Y
PIP X X X X NA Y
Small breast epithelial mucin X X X NA Y
Gamma-aminobutyric acid A
receptor, pi
X X X NA Y
Breast tumour-specific gene B726P X X NA Y
ML-1 protein X X X X NA N
FLJ22418 fis, clone HRC08590 X X X X NA N
Iroquois-class homeodomain protein
(IRX-2A)
X X X NA N
Breast tumour-specific gene B311D X X X NA N
Breast tumour-specific gene B305D X X X NA N
Breast tumour-specific gene B533S X X X NA N
Putative breast cancer-specific
markers
PDEF X X X X X X N/Y
FLJ22945 fis, clone KAT09065 X X X X N
Putative breast cancer status markers
Nonspecific cross-reacting antigen
(CEACAM-6)
X X X X NA Y
Grb7V protein X X X X NA Y
Polymorphic epithelial mucin X X X X NA Y
CK19 X X X NA Y
Troponin T1, skeletal, slow X X NA Y
S100-type calcium binding
protein A14
X X NA Y
S100 calcium-binding protein A7
(psoriasin 1)
X X NA Y
Erb-b-2 (Her2/neu) X X NA Y
Secretory Protein (P1.B) X X X NA X N
Integrin -5 Subunit X X X X NA X N
Trefoil factor 3, intestinal (TFF3) X X X X NA X N
Glycoprotein hormones, 
polypeptide (CGA)
X X X NA X N
Carboxypeptidase B1 X X NA X N
Fatty acid binding protein,
brain-type (hB-FABP)
X X NA X N
UROC28 X X X NA X N
Survivin X X NA X N
Epidermal growth factor receptor
(EGFR)
X X NA X N
Plasminogen activator, urokinase
receptor (uPAR)
X X NA X N
Synuclein,  (breast cancer-
specific gene BCSG1)
X X NA X N
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breast tissue RNA samples (16 normal/benign and 53
cancer) and 24 total RNA samples from normal and can-
cerous colon, rectal, lung, and ovarian tissues. Markers
were selected for continued testing as breast tissue-
specific markers if the following two criteria were met: 1)
expression level in breast tissue 5 copies/cell in 40%
of the breast samples tested (based on the assumption of
10 pg RNA per cell); and 2) expression levels 5 copies/
cell in 90% of ovarian, lung, and colorectal cancer
tissue RNAs tested. Genes demonstrating promise as
breast tissue-specific markers were subsequently tested
with additional samples to increase the overall breast
tissue RNA data set to 129 samples (19 normal breast, 12
benign breast disease, and 98 breast cancer RNA sam-
ples). Markers were initially screened as potential breast
cancer status markers and were selected for additional
testing if the following two criteria were met: 1) expression
level in breast tissue 5 copies/cell in 40% of the
breast samples tested (based on the assumption of 10
pg RNA per cell); and 2) detection of20% of cancerous
samples using cut-offs that detected15% of the benign
and normal breast samples tested (specificity 85%).
Markers selected for additional testing were subse-
quently tested with the 129 breast tissue RNA samples
described above and the sensitivity/specificity criteria
were further raised to 30 and 90%, respectively.
Based on the testing described above, the following
five breast tissue-specific genes were selected for further
testing as potential markers for the detection of metasta-
sis of breast cancer to sentinel lymph nodes: MG, PIP,
B305D, GABA-pi, and B726. These markers have all
been previously published as having utility in the de-
tection of metastasis of breast cancer to lymph
nodes.10,23,28 Even though B305D did not pass all of our
screening criteria, it was selected for additional testing
because it had previously been demonstrated to comple-
ment three of the other markers selected for testing.27,28
In addition, two of the breast cancer status markers iden-
tified, CK19 and PDEF, were selected for further testing in
lymph nodes. These genes were selected because 1) our
microarray and RT-PCR data demonstrated that they are
expressed at significant levels in nearly all breast can-
cers; 2) our data demonstrated that they are up-regulated
in approximately 30 to 40% of breast cancers; and 3)
both genes have previously been documented to have
utility for the detection of lymph node metastases in
breast cancer patients.26,32 PDEF also demonstrated
mean expression in breast tissue that was higher than in
the other tissues tested (even though the marker did not
meet our criteria for breast tissue specificity). Based on
the testing described above, the seven markers selected
for additional testing offered the best opportunity to iden-
tify an optimal gene for the detection of metastasis of
breast cancer to sentinel lymph nodes.
Performance of Individual Gene Markers
The seven markers selected above were tested on all
available sentinel lymph nodes from approximately 300
sentinel lymph node dissection patients. The purpose of
this testing was to identify genes whose expression
closely correlated with the histological detection of clini-
cally actionable metastasis. Initial analysis of the marker
expression data clearly identified a small number of pa-
thology-negative samples that demonstrated high levels
of signal for several of the markers tested. This observa-
tion, combined with the recognition that the histological
methods used in this study (total of three sections ana-
lyzed by H&E, representing a 100-m section of the
lymph node) would be expected to miss a subset of
samples that contained metastases 0.2 mm, led us to
test a variety of specificity cut-offs in the analysis of
marker performance. Because of the presence of signif-
icant expression of at least three genes in 6% (11 of the
183) pathology-negative patients, a specificity of 94%
was chosen for assessing the sensitivity of the individual
Figure 2. Sensitivity of markers in lymph nodes. Individual marker sensitivity
was assessed in lymph node tissues by RT-PCR. A specificity of 94% was used
to identify individual markers that offered optimal performance for detection
of clinically actionable metastases.
Figure 1. Marker selection process. Identification of breast-specific markers
and/or breast cancer-status markers was carried out using a series of four
filters: 1) expression in WBCs, 2) expression level in breast cancer tissues, 3)
expression level in normal/benign breast tissues, and 4) expression in other
epithelial cancers. Markers had to pass the first two criteria and either of the
last two criteria to be selected.
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markers (Figure 2). Based on this criterion, the highest
single gene sensitivity was observed with the epithelial
cell marker CK19 (86% sensitivity), followed by PDEF
(79% sensitivity) and the breast-specific marker mamma-
globin (73% sensitivity).
Performance of Marker Combinations
To increase sensitivity, we sought to determine the opti-
mal set of two or more genes for correlation with histol-
ogy. This optimal gene set would have the potential to
form the basis of an intraoperative assay for the detection
of metastasis in breast sentinel lymph nodes. For the
same reasons described above for the single marker
testing, optimal sensitivity of marker combinations was
also determined at a specificity of 94%, using non-
weighted ROC analysis (Figure 3). Based on these crite-
ria, the optimal marker combination was mammaglobin
plus CK19, which demonstrated 90% sensitivity at 94%
specificity (Table 4). Only one three-gene combination,
MG/CK19/B726, demonstrated an improvement in perfor-
mance, with B726 complementing one of the seven MG/
CK19-negative samples. Additional markers did not com-
plement MG/CK19/B726 in the remaining six PCR false-
negative samples. These results suggest that the majority
of observed PCR false negatives likely resulted from un-
even sampling during the splitting of sample between
PCR and pathology, rather than from lack of expression
of the individual markers being tested. This conclusion is
supported by the fact that the testing of the primary
tumors from four of the molecular false-negative patients
demonstrated substantial expression of mammaglobin
and/or CK19 in all four tumors tested (data not shown).
Additional support for this hypothesis is provided by the
fact that five of the seven false-negative samples were
characterized as micrometastases by histological
analysis.
We determined the two-gene combination of mamma-
globin and CK19 to be the optimal marker set for a variety
of reasons. First, the impact of the third gene B726 was
minimal and not convincing—the one sample detected
by B726 was weakly positive with B726 and weakly neg-
ative with CK19. Second, addition of another gene to a
multiplexed assay would likely have a negative impact on
assay performance. Finally, the low expression of B726
made it an unattractive target for an intraoperative assay,
due to the need to extend the number of thermocycles
run to determine B726 positivity (the Ct threshold used for
B726 was 5 cycles higher than the thresholds used for
mammaglobin and CK19).
Further analysis of the 11 pathology-negative samples
that were MG/CK19 positive is summarized in Tables 4
and 5. Several pieces of evidence strongly suggest that
the majority of these samples referred to as molecular
false positives are in reality true positives missed by
pathology. The frequency of RT-PCR-positive results was
similar between the pathology-positive patients and the
pathology-negative, mammaglobin/CK19-positive pa-
tients for all markers tested; in contrast, the frequency of
RT-PCR-positive results was 9- to 42-fold lower in pathol-
ogy-negative, mammaglobin/CK19-negative samples
and consistently 5% across all markers (Table 5). The
mean number of markers testing positive was identical
between the pathology-positive and the pathology-neg-
ative, mammaglobin/CK19-positive samples; in both
cases, this level was 33-fold higher than in pathology-
negative, mammaglobin/CK19-negative samples. Sev-
eral of the samples referred to as molecular false positive
are positive with all or nearly all of the seven markers
tested (Table 6). In many cases, several markers were
highly expressed (Ct values at least five cycles below the
Ct cut-off for positivity). Several of these genes are up-
regulated in breast cancer tissues and should not be
detected unless a large number of cancerous cells were
present in the sample. One of the samples categorized
as molecular false positive was actually determined to be
H&E positive on reexamination after initial identification
by IHC (following an initial diagnosis of H&E negative).
This sample, identified with an asterisk in Table 6, was
positive for five of the markers tested. The fact that the
Figure 3. Sensitivity of marker combinations in lymph nodes. Two-marker
and three-marker combinations were assessed in lymph node tissues by
RT-PCR. A specificity of 94% was used to identify marker combinations that
offered optimal performance for detection of clinically actionable metastases.
Table 4. Performance of Two-Gene Combination Relative to
Standard Histology
Formalin-fixed paraffin-embedded H&E
() without immunohistochemistry
 
MG/CK19  64 11
 7 172
Total 71 183
Sensitivity, 90%; Specificity, 94%; positive predictive value, 85%;
negative predictive value, 96%.
Table 5. Performance of RT-PCR Markers
Marker
Histology
positive
(%)
MG/CK19
positive,
histology
negative
(%)
MG/CK19
negative,
histology
negative
(%)
MG 73 82 NA
CK19 86 82 NA
PDEF 79 73 1.7
PIP 69 73 1.7
B305D 70 73 2.3
GABA 31 36 4.1
B726 59 45 3.5
Markers () 5.2 5.2 0.16
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criteria for presumptive positivity failed to call this sample
positive suggests that the criteria for identifying presump-
tive positives may be excessively stringent.
We stratified molecular marker-positive, H&E-negative
patients on the likelihood that the patients’ nodes truly
contained significant metastases that were missed by
standard pathology. Patients were deemed to be pre-
sumptively H&E positive if at least four of the seven
markers were positive, with at least one marker strongly
positive (Ct value at least five cycles below the Ct cut-off
for positivity). Applying these criteria, 6 of the 11 molec-
ular positives were presumptive H&E positives (Table 6).
When compared with both H&E positivity and presump-
tive H&E positivity, the adjusted performance of mamma-
globin and CK19 was 91% sensitivity and 97% specificity
(Table 7).
Determination of Confidence Intervals for
Performance Parameters of Optimal Two-Gene
Combination
Bootstrap analysis was used to determine 95% confi-
dence intervals for sensitivity and specificity for the
marker Ct cut-offs that gave the optimal observed sensi-
tivity at 94% specificity (Ct  31.7 for mammaglobin and
Ct  30.9 for CK19, observed sensitivity of 90%). This
analysis demonstrated 95% confidence intervals of 83 to
97% for sensitivity and 90 to 97% for specificity. Applying
the same type of analysis to the data set that included
presumptive H&E-positive results (observed sensitivity
and specificity of 91 and 97%, respectively) led to 95%
confidence intervals of 84 to 97% for sensitivity and 95 to
99.4% for specificity. The individual marker cut-offs that
gave optimal performance were unchanged.
Discussion
We have used a global strategy for identifying optimal
markers for the metastasis of breast cancer. To achieve
this, we have used a series of filters to sequentially re-
duce the number of candidate breast tissue and/or
breast cancer status gene expression markers tested to
14. Seven of these markers underwent further validation
for the detection of breast metastasis in SLNs. The ability
to test a significant number of markers on a high-density
chip has the potential to dramatically improve the prob-
ability of selecting markers that meet specific diagnostic
requirements. Our results strongly suggest that microar-
ray analysis is an ideal method of predicting success for
markers previously published as having desirable ex-
pression behavior. Eight of the 10 literature markers also
identified by microarray analysis passed our screening
criteria for utility as breast tissue-specific or breast
cancer status markers. In contrast, only 3 of the 13 mark-
ers identified by literature but not confirmed by microar-
ray analysis were deemed to provide acceptable
performance.
In addition to demonstrating the utility of combining
literature and microarray methods in the marker selection
process, we also report here the identification of an op-
timal two-gene expression marker set for detection of
clinically actionable metastasis in breast sentinel lymph
nodes. The two specific markers identified, mammaglo-
bin and CK19, have been previously published as poten-
tially useful components of multimarker panels for the
identification of occult metastasis in breast lymph
nodes.12,32,33 However, previous studies have also con-
cluded that both markers are expressed in the lymph
nodes of 20 to 40% of patients categorized as lymph
node negative by standard histological analysis.10,11 It
has also been reported that lymph nodes from a high
percentage of cancer-free patients express CK19.34,35
This report represents the first statistically significant data
set demonstrating the feasibility of using a combination of
molecular markers for the detection of clinically action-
able metastases in breast lymph nodes. We have subse-
quently developed a rapid RT-PCR assay using mamma-
globin and CK19 that generates a result in 30 minutes
from lymph node tissue (J. Backus, G. Green, M. Xu, J.
Painter, S. Varde, unpublished data).
One of the challenges in accurately determining the
specificity of this molecular assay is the relatively high
false-negative rate observed with standard H&E pathol-
ogy interpretation. Estimates of the true false-negative
rates for the detection of metastases range from 5 to
15%.36,37 Analysis of the seven molecular markers tested
demonstrated that the majority of mammaglobin/CK19
molecular false positives were also positive with several
other breast tumor markers not expressed in the vast
majority of H&E-negative samples. Samples demonstrat-
Table 6. Identification of Presumptive Positive Patients
Patient MG VBM1
Total no. of
markers
positive
Markers
strongly
positive
Presumptive
positive
1   7 6 
2  5 4 
3   7 3 
4   7 3 
5   4 3 
6   4 1 
7  2 1
8  2 1
9   6 0
10*   5 0
11  1 0
, PCR positive (Ct  cut-off); , strongly PCR positive (5
cycles below Ct cut-off); Presumptive positive, PCR positive with 4
markers, strongly PCR positive with 1 marker.
* Sample detected by H&E only after immunohistochemistry.
Table 7. Performance of Two-Gene Combination Relative to
Presumptive Positivity
Formalin-fixed paraffin-embedded H&E
() or presumptive ()
 
MG/CK19  70 5
 7 172
Total 77 177
Sensitivity, 91%; Specificity, 97%; PPV, 93%; NPV, 96%.
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ing significant expression of mammaglobin and/or CK19
have a high probability of also expressing the other mark-
ers tested, including B305D, GABA, B726, and PDEF,
markers previously demonstrated to have increased ex-
pression in cancerous breast tissues.27,28 A significant
conclusion from this testing is that any clinical study
designed to determine correlation between a molecular
assay and standard H&E pathology needs to employ
comprehensive H&E analysis to minimize the risk of not
detecting clinically significant metastases, leading to
false-negative H&E results that will be subsequently in-
terpreted as molecular false-positive results.
A major criticism of RT-PCR detection of occult metas-
tasis is that it can be too sensitive, detecting as little as
one copy of RNA for genes that can be expressed at
levels of 1000 copies/cell. By using quantitative PCR
with thresholds based on clinical samples, a clinically
significant level of RNA expression can be determined,
minimizing the risk of false-positive results. The threshold
used for mammaglobin in this testing, for instance, cor-
relates to the presence of approximately 10,000 copies of
RNA in the amplification reaction, which uses a median of
approximately 0.03% of the total RNA in a typical tissue
sample. Assuming expression of 1000 copies of mam-
maglobin mRNA per cell, a positive sample would repre-
sents a minimum of approximately 70,000 cells express-
ing mammaglobin in the original sample. This is more
than 10-fold more cells than would be expected to be
present in a 0.2-mmmicrometastasis, suggesting that the
thresholds developed are consistent with the detection of
clinically significant metastasis, although biased toward
specificity at the cost of sensitivity. We believe this per-
formance bias to be appropriate for application of the
gene set to an intraoperative assay designed to direct
additional axillary lymph node dissection. This perfor-
mance bias would also be expected to minimize the risk
of detecting benign lesions that are infrequently ob-
served in breast lymph nodes. These lesions are typically
small and only visualized with the assistance of
immunohistochemistry.
In summary, we have used a whole-genome approach,
using a series of filters, to identify gene expression mark-
ers that correlate with standard histological detection of
breast lymph node metastasis with high sensitivity and
specificity. A variety of data and a large body of literature
evidence support the conclusion that most of the discrep-
ancies that do exist between the RT-PCR assay and
standard permanent section H&E results represent sam-
pling errors between the two methods used. We further
demonstrate that analysis of two marker genes, mamma-
globin and CK19, can form the basis of a rapid RT-PCR
assay for the detection of clinically actionable metasta-
ses. We have subsequently developed a rapid assay
based on this marker set and are in the process of
validating the clinical performance of this assay. Such an
assay has the potential to lead to a significant reduction
in the number of unnecessary second surgeries to re-
move axillary lymph nodes in sentinel lymph node-posi-
tive patients.
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